A team of Australian researchers has found no evidence that opioids are more effective than placebos in managing lower back pain in middle-aged individuals.

Deucravacitinib (Sotyktu): First-In-Class, Allosteric Tyrosine Kinase 2 (Tyk2) Inhibitor For Adults With Moderate-To-Severe Plaque Psoriasis Approved

By Rachel TanJune 29, 20230

A new oral option for moderate-to-severe plaque psoriasis has emerged. Clinical trials show deucravacitinib delivering stronger efficacy than apremilast, offering a fresh approach after nearly a decade without major oral treatment innovation.

Singapore Withdraws Popular Cough Medicine Due To Health Risks

By Gerald NgJune 27, 20230

The Health Sciences Authority (HSA) in Singapore has made a regulatory decision to withdraw pholcodine-containing products from the market. This ban affects the range of cough liquids and lozenges from the brand Duro-Tuss & Difflam.

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

What's Hot

AI in the Heart Room

World Cup 2026: The Orthopaedic Toll Of Football’s Biggest Stage

Why Is Robotic Surgery Becoming More Common?

Browsing: Medication & Drugs

Key to Malaysia’s Post-COVID-19 Recovery: Boosting Mitochondrial Health, New Studies Suggest

Preventing Drug Interactions: Tips and Common Interactions

Brexipiprazole: FDA Approves First Drug to Treat Dementia-Related Agitation Symptoms

Etrasimod: New Treatment Option for Ulcerative Colitis

Zavicefta: Life-Saving Antibiotic for Carbapenemase-Producing Enterobacterales

Opioid Medicine: FDA Updates Prescribing Information and Warnings

Pholcodine withdrawn – ALPHO case-control study

Opioids No Better than Placebos in Mitigating Mid-40s Lower Back Pain, Study Finds